Get started

Pharmaceuticals

AFT Pharma Trading at Support Level BUY OPPORTUNITY NOWThis is a simple support & resistance analysis of this stocks current price level. The stock is at a price level which can be said as a good established support level, the last time the stock was here it was almost 3 months ago and it made good gains after touching this level. If anyone beleives there are other reasons for why this stock will continue to fall below support, please comment ASAP! Im going long on this one now...
NZX:AFTLong
by WineTrader888
Aspen analysis Aspen had a positive week with a good rebound at R 107. This seems to be a good support line as the price is struggling a bit to go below this point. Currently sitting at R121, this could be a welcomed reset as we can expect the price to approach support again possibly in the new week depending on market sentiment overall. On the business end Aspen seems to be doing quite well, and we are certainly hoping this does reflect soon in terms of share price. From 105 to peak of 154, would yield a healthy 46% return which has a good chance of being realized in future. For now its a hold and those wanting to buy in would probably watch to see if a pull back is on the table.
JSE:APN
by AfroTez
Pharmamar PHMGood morning, today I present the analysis of PHM, a Spanish company pharmamar in the race for the vaccine against Covid19. It is being a great trading year for this company. The bullish structure marked by the yellow arrow has been broken, but the new structure, the bearish one, has not yet consolidated. You have marked supports and resistances to see possible changes in trend ... We mark some of them, the purple and blue arrows. Sincerely L.E.D Be Safe!! In Spain on 10/20/2020
BME:PHMLong
by wallstreetstocks
BioNTech Stock Will Soar With Its First-Mover Vaccine AdvantageNASDAQ:BNTX a German company and its american partner NYSE:PFE will likely have a first-mover advantage in the coronavirus vaccine race in the U.S. This will affect both stocks, once the final vaccine results are in. Assuming the bottom is in and we are about to continue the Trend as previously, im expecting a big move after the approval, so dont forget to take risk of the table! The reason for this is that the two companies are expecting to be the first to produce large-scale results from their Phase 2/3 clinical trials in October, according to Barron’s. Depending on how effective their vaccine is, the U.S. Food and Drug Administration may even grant it emergency-use authorization The advantage of their trial is that it is large, involving more than 30,000 participants. The FDA wants to see at least 50% efficacy in trials before granting any Covid-19 authorization. Why BioNTechs Vaccine Looks Like a Winner With Pfizer in the back FDA and President Donald Trump are likely to move quickly. According to them even the first small study with 24 Persons that took their messenger RNA vaccine produced antibodies. With a lower doses usage of the vaccine and developed antibodies after 28 days — at levels about two times higher than in normal, recovering Covid-19 patients. BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 to Hong Kong SAR and Macao SAR Also a Deal to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidat This combined with the huge buying volume and market shifts will grant momentum for bigger goals. Just think about what ccould happen when they get kinda a monopol situation going for them. Thank you for take the time and reading this and as always stay storng in those shaky times! Sebastian
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
4